Madame Brigitte Macron visits Yposkesi, a European leader in viral vector manufacturing
Yposkesi enters into agreement in principle for strategic partnership with Axovant to expand Axovant gene therapy manufacturing capacity
In the framework of a preferred partnership, Yposkesi plans to grant Axovant access to dedicated cGMP capacity and manufacturing resources to further support the global development and commercialization of Axovant’s…
Yposkesi appoints Dr. Fraser Wright as senior advisor
With extensive experience in gene therapy vector manufacturing, Dr. Wright, scientific co-founder and former CTO of Spark Therapeutics, will support Yposkesi’s innovation in viral vector design, production and characterization.